A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
← catalyst calendarSponsored by Viridian Therapeutics, Inc. (industry) · VRDN — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
87actual
Sites
13
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-01 | actual | When the study began enrolling |
| Primary completion | 2026-05-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-28 | actual | The whole study's end, after follow-up |
| First posted | 2025-09-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Thyroid Eye Disease
Interventions
- Drug: VRDN-003
- Device: Autoinjector
Primary outcome
what the primary-completion date above is the date OFTreatment Emergent Adverse Event (TEAE) incidence rate
measured Through Week 24
Permalink · VRDN's whole pipeline · Catalyst calendar · Every registered study · What changed